Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical company specializing in the development, manufacturing, and commercialization of innovative medicines across specialty and primary care, consumer healthcare, and rare diseases. Headquartered in Milan, Italy, it traces its origins to a family-run pharmacy in the 1920s and now operates in approximately 150 countries with over 4,500 employees, 10 production sites, and fully integrated operations from research and development to licensing. The company focuses on therapeutic areas including cardiovascular, urological, gastrointestinal, cough and cold therapies for common conditions, and metabolic, endocrinology, and hema-oncology for rare diseases, benefiting over 100 million patients annually from its specialty portfolio and 16,000 from rare disease treatments. Recordati invests significantly in R&D, spending 286 million euros in 2024, advancing products like Enjaymo for cold agglutinin disease, Isturisa for Cushing's syndrome, and a robust pipeline including Qarziba and REC 0545. It produces active pharmaceutical ingredients for internal use and third parties, emphasizing sustainable growth, innovation, and a culture of entrepreneurship and inclusion.